中风与神经疾病杂志2017，Vol.34Issue(8)：725-728,4.
非标准剂量阿替普酶静脉溶栓治疗急性缺血性卒中
Non standard-dose intravenous alteplase in acute ischemic stroke
摘要
Abstract
Objective To compare the efficacy and safety of non standard-dose and standard-dose intravenous alteplase in Chinese patients with acute ischemic stroke.Methods Eligible patients from Peking University Shenzhen Hospital were consecutively enrolled into the study from 2007 to 2015.According to the dose of alteplase received for managing acute ischemic stroke,they were divided into 2 groups:the non standard-dose (0.521～0.833 mg/kg) and the standard-dose (0.9 mg/kg).We analyzed symptomatic intracranial hemorrhage (SICH),mortality and 90 day outcome of these patients.Results Modified Rankin Scale before thrombolysis were 0.Among them,48 had 0.521～0.833 mg/kg,median alteplase doses were 0.7245 mg/kg,as an non standard-dose group,and 51 had 0.9 mg/kg as a standard-dose group.Median NIHSS score before thrombolysis were both 13.Median time from stroke onset to needle were 200.75 min and 197.53 min,respectively.After adjustment for the baseline variables,no significant differences were found between the 2 groups in symptomatic intracranial hemorrhage (8.33% vs 5.88%,P=0.727),mortality(6.25% vs 9.8%,P=0.796),mRS score 0～2 (64.58% vs 64.71%,P=0.641)or mRS score 0～1 (56.25% vs 49.02%,P=0.645).Conclusion The efficiency and safety of non standard-dose intravenous alteplase are same with the standard-dose for acute ischemic stroke.And the optimum dose may be another one between 0.6 mg/kg to 0.9 mg/kg for Chinese patients.关键词
急性缺血性卒中/静脉溶栓/阿替普酶/剂量Key words
Acute ischemic stroke/Intravenous thrombolysis/Alteplase/Dose分类
医药卫生引用本文复制引用
丘红燕,彭伟彬,胡俊,吴军..非标准剂量阿替普酶静脉溶栓治疗急性缺血性卒中[J].中风与神经疾病杂志,2017,34(8):725-728,4.基金项目
深圳市战略新兴产业发展专项资金(No.JCYJ20150605103420338) （No.JCYJ20150605103420338）
